Caris Life Sciences
Irving
About Caris Life Sciences
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology. The company offers a comprehensive tumor profiling service known as Caris Molecular Intelligence, which analyzes DNA, RNA, and proteins to help oncologists identify potential treatment options. Caris also operates a platform called Caris CODEai that integrates molecular data with clinical outcomes to support research and drug development. Its services cater to biopharma partners, healthcare providers, and academic institutions aiming to improve cancer diagnostics and therapy selection. The company incorporates machine learning models to discover new biomarkers and therapeutic targets based on large-scale multi-omic data.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Total funding: $1.9B
- Funding stage: IPO
- Last round: Private Equity (Apr 2025)
- Ticker: nasdaq:CAI
- Website: carislifesciences.com
- Phone: +1 888 979 8669
Industries & Categories
Artificial Intelligence (AI), Biopharma, Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/caris-life-sciences-13786 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.